Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Acknowledgement to Referees

Acknowledgement to Referees American Journal of Cardiovascular Drugs (2021) 21:585–588 https://doi.org/10.1007/s40256-021-00507-4 © Springer Nature Switzerland AG 2021 Dear Reader, Welcome to the final issue of the American Journal of Cardiovascular Drugs for 2021. I wish to reflect on this year’s achievements, and to thank all those who have contributed their time and effort to guarantee the quality of the content published in the journal. In 2021, over 60 articles have been published. The most popular of these in terms of downloads from SpringerLink have been: • Angoulvant D, Sabouret P, Savage MP. NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. Am J Cardiovasc Drugs 21, 483–486 (2021). https://doi. or g/10. 1007/ s40256- 021- 00471-z . • Ashton V, Mudarris L, Moore KT. The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations. Am J Cardiovasc Drugs 21, 283–297 (2021). https:// doi. org/ 10. 1007/ s40256- 020- 00434-w. • Galo J, Celli D, Colombo R. Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Direc- tions. Am J Cardiovasc Drugs 21, 267–270 (2021). https:// doi. org/ 10. 1007/ s40256- 020- 00445-7. • Vong C, Boucher M, Riley S, et al. Modeling of Survival and Frequency of Cardiovascular-Related http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Acknowledgement to Referees

American Journal of Cardiovascular Drugs , Volume 21 (6) – Nov 1, 2021

Loading next page...
 
/lp/springer-journals/acknowledgement-to-referees-e9feWlee0V
Publisher
Springer Journals
Copyright
Copyright © Springer Nature Switzerland AG 2021
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-021-00507-4
Publisher site
See Article on Publisher Site

Abstract

American Journal of Cardiovascular Drugs (2021) 21:585–588 https://doi.org/10.1007/s40256-021-00507-4 © Springer Nature Switzerland AG 2021 Dear Reader, Welcome to the final issue of the American Journal of Cardiovascular Drugs for 2021. I wish to reflect on this year’s achievements, and to thank all those who have contributed their time and effort to guarantee the quality of the content published in the journal. In 2021, over 60 articles have been published. The most popular of these in terms of downloads from SpringerLink have been: • Angoulvant D, Sabouret P, Savage MP. NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. Am J Cardiovasc Drugs 21, 483–486 (2021). https://doi. or g/10. 1007/ s40256- 021- 00471-z . • Ashton V, Mudarris L, Moore KT. The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations. Am J Cardiovasc Drugs 21, 283–297 (2021). https:// doi. org/ 10. 1007/ s40256- 020- 00434-w. • Galo J, Celli D, Colombo R. Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Direc- tions. Am J Cardiovasc Drugs 21, 267–270 (2021). https:// doi. org/ 10. 1007/ s40256- 020- 00445-7. • Vong C, Boucher M, Riley S, et al. Modeling of Survival and Frequency of Cardiovascular-Related

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Nov 1, 2021

There are no references for this article.